Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

Novartis building

Novartis pulls EMA application for expanded Tasigna use

And Boehringer confirms it won't seek approval for faldaprevir as it exits hepatitis C

- PMLiVE

Biosimilar Lantus leads CHMP opinions

Boehringer and Lilly’s insulin one of six new medicines recommended for EU approval

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

- PMLiVE

Boehringer pulls faldaprevir and exits hepatitis C market

Unable to challenge all-oral options from Gilead and others

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

Boehringer gets ‘kite mark’ for health information

First pharma company awarded The Information Standard Certification in UK

National Institute for Health and Care Excellence NICE logo

NICE guidelines on statins will ‘medicalise’ the healthy, say doctors

Prominent physicians call for rethink on plans to lower treatment threshold

- PMLiVE

Pradaxa cleared for new indications in Europe

Boehringer drug set for use in deep vein thrombosis and pulmonary embolism

- PMLiVE

Boehringer aims for nintedanib approval in lung fibrosis by year end

EMA grants accelerated assessment to drug in rare disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links